Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Human MicroRNA Panel for gene-expression profiling to be launched by WaferGen Biosystems

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced that it will be launching the Human MicroRNA Panel for its innovative service for gene-expression profiling using its SmartChip(TM) Real-Time PCR System.

17 Dec 2009

Thomson Reuters offers integrated clinical trial protocol and outcome information for customers

Thomson Reuters today announced that Thomson Pharma® has become the first drug pipeline database to fully integrate detailed clinical trial protocol and outcome information. This highly anticipated new content is being provided to all Thomson Pharma customers this month.

16 Dec 2009

EDP Biotech develops a simple blood test for detecting early-stage colon cancer

Medical researchers with EDP Biotech Corporation (EDP) have captured national attention with their revolutionary new technology for a simple blood test to detect early-stage colon cancer.

16 Dec 2009

IDBS included in recent research report from Gartner

IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that it has been included in a recent research report from Gartner, "Who's Who in Interactive Visualization for BI," by James Richardson, published November 13, 2009.

15 Dec 2009

Sword Diagnostics receives patent on improved sensitivity technology for detection of biological organisms

Sword Diagnostics, Inc. is pleased to announce that the United States Patent Office (USPTO) has issued patent number 7,599,057 titled "Method and Apparatus for Detection of Biological Organisms using Raman Scattering" to the company.

15 Dec 2009

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

The ALS Therapy Development Institute (ALS TDI) and Applied Proteomics, Inc. announced today that they have completed the first stage of a multi-year collaboration to identify and validate protein biomarkers associated with amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).

15 Dec 2009

Prize4life partners with Jackson Laboratory on AML research

Prize4Life, an organization dedicated to finding a cure for amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), is partnering with The Jackson Laboratory to help more researchers identify treatment candidates that increase the lifespan of mice that model ALS.

11 Dec 2009

Cardiac myosin-binding protein C identified as potential new diagnostic biomarker for heart attacks

Though they remain a leading killer, heart attacks can be effectively treated provided they can be rapidly diagnosed following initial onset of symptoms. In a study appearing in this month's Molecular and Cellular Proteomics, researchers have identified cardiac myosin-binding protein C (cMyBP-C) as a potential new diagnostic biomarker for heart attacks, one that may be particularly valuable for mild attacks in which traditional diagnostic proteins may not be abundant enough.

11 Dec 2009

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%

11 Dec 2009

Cequent Pharmaceuticals' IND application for CEQ508 approved for clinical trial

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) approved Cequent's first IND (investigational new drug) application yesterday.

10 Dec 2009

Cardiologists receive K23 research grant from NIH

Brian H. Annex, M.D., chief of the Division of Cardiovascular Medicine at the University of Virginia Health System, says he feels like the coach of a championship team. "Going three for three is truly extraordinary," he says with a mixture of pride and awe in his voice.

10 Dec 2009

Waters begins shipping its ground-breaking SYNAPT G2 Mass Spectrometer

Waters Corporation announced today that it has shipped the first units of its ground-breaking SYNAPT(TM) G2 Mass Spectrometer, first introduced at the 2009 American Society of Mass Spectrometry (ASMS) annual conference in Philadelphia in June.

9 Dec 2009

GPEC receives unrestricted grant of $250,000 to study new treatments for breast cancer

Located at Vancouver General Hospital and a partner of the BC Cancer Agency, the Genetic Pathology Evaluation Centre, led by three prominent pathologists, is a recognized world leader in cancer research in the area of biomarker technology. Today, with an additional unrestricted grant of $250,000 from sanofi-aventis, GPEC is ready to make even more scientific breakthroughs.

9 Dec 2009

New IME-developed cardiac biomarker testing system saves time

Scientists at Singapore's Institute of Microelectronics (IME) have developed a rapid and sensitive integrated system to test simultaneously for specific cardiac biomarkers in finger prick amount of blood.

9 Dec 2009

ACR Image Metrix named as industry leader by Life Science Leader magazine

ACR Image Metrix™, an imaging contract research organization (CRO) located in Philadelphia, Pennsylvania, is pleased to announce that Mehdi Adineh, Ph.D., scientific director of the imaging core laboratory of the American College of Radiology (ACR), has been named an industry leader by Life Science Leader magazine.

9 Dec 2009

Biomarkers can be important in identifying PTSD symptoms, says researchers

Veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) frequently experience high rates of PTSD along with symptoms of depression and pain. However, little is known about why these symptoms occur together or the most effective treatments that can be used to alleviate them. One approach that may yield new insights is to search for biomarkers -- indicators of a biological state that can be easily and reliably measured in people with an illness -- to see if their presence or absence can predict symptoms that an individual will experience and identify optimal treatment strategies.

9 Dec 2009

Erbitux gaining market share of Avastin in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.

8 Dec 2009

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

Onconova Therapeutics, Inc. today announced promising results from two clinical trials in patients with advanced Myelodysplastic Syndrome (MDS) treated with ON 01910.Na. These trials are being conducted at the National Heart, Lung, and Blood Institute (NHLBI) in Bethesda, MD, and St. Vincent’s Comprehensive Cancer Center in New York.

8 Dec 2009

Study: Besides nerves, skin has a unique sensory system

The human sensory experience is far more complex and nuanced than previously thought, according to a groundbreaking new study published in the December 15, 2009 issue of the journal Pain (http://www.painjournalonline.com/article/S0304-3959%2809%2900526-0/abstract).

8 Dec 2009

Cell Biosciences expands its protein analysis business with Protein Forest acquisition

Cell Biosciences, Inc. today announced that it has acquired Protein Forest, Inc. of Lexington, Massachusetts, a leader in sample preparation technology for proteomic analysis and biomarker discovery.

7 Dec 2009